Robust metabolic pipeline focused on NASH and rare metabolic diseases

Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases.

The Company also has one product, TWYMEEG® (Imeglimin), approved in 2021, now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and expects to receive royalties and sales-based payments.

VIEW OUR CANDIDATES

Latest News

Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases…

Read this Press Release: Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event

Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Fibrosis improvement by >1 stage without worsening of NASH, an endpoint…

Read this Press Release: Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

 Results support the development of PXL770 in a Phase 2 clinical program for ADPKD LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage…

Read this Press Release: Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

An expertise focused on targeting mitochondrial dysfunction

The Company’s most advanced clinical products - PXL065, PXL770 and Imeglimin (now commercialized in Japan) - address significant targets in the energy metabolism pathways

View Our Candidates
An expertise focused on targeting mitochondrial dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams combines the know-how and experience to successfully develop products, such as Imeglimin, which is marketed by our partner Sumitomo Pharma in Japan since 2021.

Meet Our Team
Backed by Strong Leadership